S&P 500   4,554.70 (-0.27%)
DOW   34,298.85 (-0.54%)
QQQ   389.87 (-1.00%)
AAPL   165.15 (-0.09%)
MSFT   332.88 (+0.69%)
FB   312.55 (-3.67%)
GOOGL   2,847.36 (+0.33%)
AMZN   3,454.63 (-1.50%)
TSLA   1,095.52 (-4.30%)
NVDA   316.15 (-3.25%)
BABA   123.17 (-3.42%)
NIO   38.47 (-1.69%)
CGC   9.99 (-6.72%)
AMD   150.31 (-5.09%)
GE   94.13 (-0.91%)
MU   86.01 (+2.39%)
T   22.33 (-2.19%)
F   19.77 (+3.02%)
DIS   142.99 (-1.32%)
AMC   28.45 (-16.18%)
PFE   54.80 (+1.99%)
ACB   6.01 (-6.39%)
BA   190.91 (-3.51%)
S&P 500   4,554.70 (-0.27%)
DOW   34,298.85 (-0.54%)
QQQ   389.87 (-1.00%)
AAPL   165.15 (-0.09%)
MSFT   332.88 (+0.69%)
FB   312.55 (-3.67%)
GOOGL   2,847.36 (+0.33%)
AMZN   3,454.63 (-1.50%)
TSLA   1,095.52 (-4.30%)
NVDA   316.15 (-3.25%)
BABA   123.17 (-3.42%)
NIO   38.47 (-1.69%)
CGC   9.99 (-6.72%)
AMD   150.31 (-5.09%)
GE   94.13 (-0.91%)
MU   86.01 (+2.39%)
T   22.33 (-2.19%)
F   19.77 (+3.02%)
DIS   142.99 (-1.32%)
AMC   28.45 (-16.18%)
PFE   54.80 (+1.99%)
ACB   6.01 (-6.39%)
BA   190.91 (-3.51%)
S&P 500   4,554.70 (-0.27%)
DOW   34,298.85 (-0.54%)
QQQ   389.87 (-1.00%)
AAPL   165.15 (-0.09%)
MSFT   332.88 (+0.69%)
FB   312.55 (-3.67%)
GOOGL   2,847.36 (+0.33%)
AMZN   3,454.63 (-1.50%)
TSLA   1,095.52 (-4.30%)
NVDA   316.15 (-3.25%)
BABA   123.17 (-3.42%)
NIO   38.47 (-1.69%)
CGC   9.99 (-6.72%)
AMD   150.31 (-5.09%)
GE   94.13 (-0.91%)
MU   86.01 (+2.39%)
T   22.33 (-2.19%)
F   19.77 (+3.02%)
DIS   142.99 (-1.32%)
AMC   28.45 (-16.18%)
PFE   54.80 (+1.99%)
ACB   6.01 (-6.39%)
BA   190.91 (-3.51%)
S&P 500   4,554.70 (-0.27%)
DOW   34,298.85 (-0.54%)
QQQ   389.87 (-1.00%)
AAPL   165.15 (-0.09%)
MSFT   332.88 (+0.69%)
FB   312.55 (-3.67%)
GOOGL   2,847.36 (+0.33%)
AMZN   3,454.63 (-1.50%)
TSLA   1,095.52 (-4.30%)
NVDA   316.15 (-3.25%)
BABA   123.17 (-3.42%)
NIO   38.47 (-1.69%)
CGC   9.99 (-6.72%)
AMD   150.31 (-5.09%)
GE   94.13 (-0.91%)
MU   86.01 (+2.39%)
T   22.33 (-2.19%)
F   19.77 (+3.02%)
DIS   142.99 (-1.32%)
AMC   28.45 (-16.18%)
PFE   54.80 (+1.99%)
ACB   6.01 (-6.39%)
BA   190.91 (-3.51%)
LON:MXCT

MaxCyte Share Forecast, Price & News

GBX 750
+38.00 (+5.34%)
(As of 12/1/2021 03:21 PM ET)
Add
Compare
Today's Range
720
765
50-Day Range
680
1,223
52-Week Range
380
1,235
Volume
110,959 shs
Average Volume
183,705 shs
Market Capitalization
£755.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive MXCT News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.


MaxCyte logo

About MaxCyte

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Headlines

CEO Of Maxcyte Trades $3.7M In Company Stock
November 17, 2021 |  finance.yahoo.com
MaxCyte (LON:MXCT) Shares Up 6.1%
November 13, 2021 |  americanbankingnews.com
MaxCyte, Inc. (MXCT) Q3 2021 Earnings Call Transcript
November 12, 2021 |  finance.yahoo.com
MaxCyte to Participate in Upcoming Investor Conferences
November 12, 2021 |  finance.yahoo.com
MaxCyte, Inc.: MaxCyte Reports Third Quarter Financial Results
November 10, 2021 |  finanznachrichten.de
MaxCyte Reports Third Quarter Financial Results
November 10, 2021 |  finance.yahoo.com
MaxCyte, Inc. : License with Nkarta, Inc.
November 3, 2021 |  markets.businessinsider.com
MaxCyte, Inc. : Result of AGM
October 31, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
65
Year Founded
N/A

Sales & Book Value

Annual Sales
£32.26 million
Cash Flow
GBX 245.55 per share
Book Value
GBX 263 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£755.73 million
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.94 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












MaxCyte (LON:MXCT) Frequently Asked Questions

Is MaxCyte a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MaxCyte stock.
View analyst ratings for MaxCyte
or view top-rated stocks.

How has MaxCyte's stock been impacted by COVID-19?

MaxCyte's stock was trading at GBX 150 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MXCT stock has increased by 400.0% and is now trading at GBX 750.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MXCT?

1 Wall Street analysts have issued 1-year price objectives for MaxCyte's stock. Their forecasts range from GBX 1,240 to GBX 1,240. On average, they anticipate MaxCyte's stock price to reach GBX 1,240 in the next year. This suggests a possible upside of 65.3% from the stock's current price.
View analysts' price targets for MaxCyte
or view top-rated stocks among Wall Street analysts.

Who are MaxCyte's key executives?

MaxCyte's management team includes the following people:
  • Mr. Douglas Arthur Doerfler, Founder, Pres, CEO & Exec. Director (Age 65, Pay $705.25k)
  • Mr. Ronald Evan Holtz Ph.D., CPA, Sr. VP, Chief Accounting Officer, Company Sec. & Exec. Director (Age 63, Pay $445.93k)
  • Ms. Amanda Louise Murphy C.F.A., CFA, Chief Financial Officer
  • Mr. Maher Masoud, Exec. VP & Gen. Counsel
  • Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 60)
  • Mr. Markus J. Hunkeler, VP of Marketing
  • Dr. Claudio Dansky Ullmann M.D., Chief Medical Officer
  • Ms. Shruti Abbato, Exec. VP of Bus. Devel. for CARMA Cellular Therapies

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), (ATE), Astrotech (ASTC), Arcturus Therapeutics (ARCT), (AQB), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC).

What is MaxCyte's stock symbol?

MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT."

How do I buy shares of MaxCyte?

Shares of MXCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately GBX 750.

How much money does MaxCyte make?

MaxCyte has a market capitalization of £755.73 million and generates £32.26 million in revenue each year.

How many employees does MaxCyte have?

MaxCyte employs 65 workers across the globe.

What is MaxCyte's official website?

The official website for MaxCyte is www.maxcyte.com.

Where are MaxCyte's headquarters?

How can I contact MaxCyte?

MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The company can be reached via phone at +1-301-9441700.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.